Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Finerenone was beneficial in primary and secondary prevention across the spectrum of patients with ...
Three separate papers on the kidney drug finerenone landed in the New England Journal of Medicine, The Lancet, and JAMA on the same day, each reporting that the drug met its primary endpoints. The ...
A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...
A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD. Rajiv Agarwal, MD, MS: Before I ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A subanalysis of the FIDELITY trial showed finerenone ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new cardiovascular (CV) and renal subgroup analyses for KERENDIA ® (finerenone) from the comprehensive clinical trial program, including the ...
Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia) clinical trial programme, including the phase III FIGARO-DKD and FIDELIO-DKD studies, and the ...
New signals of a potential additive benefit from the nonsteroidal mineralocorticoid antagonist finerenone (Kerendia) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with type 2 ...
Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points. Rajiv Agarwal, MD, MS: The primary end point in the FIGARO-DKD ...
Reduction in the risk for heart failure hospitalization appears to drive a cardiovascular benefit. Finerenone may reduce cardiovascular risk in a wide range of patients with type 2 diabetes (T2D) and ...
Prescription pills Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators. Finerenone may prevent pneumonia and COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results